* Arranged meeting with FDA to clear doubts on lead product
* Seeks debt/equity financing to continue operations
* Met Nasdaq panel to discuss continued listing
Feb 9 A.P. Pharma Inc APPA.O said it arranged
a meeting with U.S. health regulators to clarify issues before
resubmitting an approval application for its lead product, and
is seeking financing to fund its operations beyond the second
Last March, the U.S. Food and Drug Administration declined
to approve the drug, citing concerns regarding the drug's
two-syringe administration system, and asked for more studies.
The company expects to determine the resources and timeline
needed for resubmitting the new drug application for APF530
after the meeting, it said in a statement.
APF530 is being developed for the treatment of nausea
induced by chemotherapy.
Separately, A.P. Pharma said it met with the Nasdaq Listing
and Qualifications Panel after it received a letter in November
stating it was subject to delisting. It is now awaiting the
panel's decision on its eligibility for continued listing.
Shares of the California-based company closed at 52 cents
Tuesday on Nasdaq.
(Reporting by Rajarshi Basu and Krishnakali Sengupta in
Bangalore; Editing by Sriraj Kalluvila)